These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19060551)

  • 1. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
    Danger R; Giral M; Soulillou JP; Brouard S
    Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the early elimination of calcineurin inhibitors result in clinical benefits?
    Weir MR
    Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
    Sommerer C; Giese T; Meuer S; Zeier M
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
    Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
    Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low-toxicity immunosuppressive therapy in renal transplant].
    Scolari F; La Manna G; Comai G; Cappuccilli ML; Todeschini P; Ciavatti A; Persici E; Feliciangeli G; Stefoni S
    G Ital Nefrol; 2007; 24 Suppl 38():44-8. PubMed ID: 17922447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic allograft nephropathy.
    Najafian B; Kasiske BL
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):149-55. PubMed ID: 18277147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 13. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
    Schena FP; Maiorano A; Rossini M
    G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Out with the old, in with the new: immunosuppression minimization in children.
    Sarwal MM
    Curr Opin Organ Transplant; 2008 Oct; 13(5):513-21. PubMed ID: 19060535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression in renal transplantation: some aspects for the modern era.
    Chadban S; Morris R; Hirsch HH; Bunnapradist S; Arns W; Budde K
    Transplant Rev (Orlando); 2008 Oct; 22(4):241-51. PubMed ID: 18657962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNIs: immediate benefits but storing problems for the future?
    Kiuchi T
    Transplantation; 2008 Oct; 86(8):1026-7. PubMed ID: 18946338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin nephrotoxicity.
    Williams D; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jan; 13(1):47-55. PubMed ID: 16412970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.
    Conti DJ; Petrov R; Elbalhoul O; Gallichio M
    Transpl Immunol; 2008 Nov; 20(1-2):12-3. PubMed ID: 18793727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression for heart transplantation: where are we now?
    Kobashigawa JA; Patel JK
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):203-12. PubMed ID: 16568129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for immunosuppression in lung transplantation.
    Hopkins PM; McNeil K
    Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.